Free Trial

Arbutus Biopharma (ABUS) SEC Filings & 10K Form

Arbutus Biopharma logo
$3.64 +0.04 (+0.97%)
As of 01:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Recent Arbutus Biopharma SEC Filings

DateFilerForm TypeView
04/23/2025
5:00 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/21/2025
1:11 PM
Arbutus Biopharma (Subject)
McElhaugh Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/15/2025
3:27 PM
Arbutus Biopharma (Subject)
McElhaugh Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/01/2025
4:47 PM
Arbutus Biopharma (Issuer)
Nguyen Tuan (Reporting)
Form 4/A
03/31/2025
8:42 AM
Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/27/2025
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/27/2025
6:31 AM
Arbutus Biopharma (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/24/2025
8:19 AM
Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/20/2025
3:08 PM
Androski Lindsay (Reporting)
Arbutus Biopharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/20/2025
3:10 PM
Arbutus Biopharma (Issuer)
Beardsley Robert A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/19/2025
8:34 AM
Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/07/2025
1:59 PM
Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/06/2025
3:07 PM
Arbutus Biopharma (Issuer)
Gline Matthew (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/06/2025
3:08 PM
Androski Lindsay (Reporting)
Arbutus Biopharma (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
03/06/2025
3:10 PM
Arbutus Biopharma (Issuer)
Beardsley Robert A (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/06/2025
3:11 PM
Arbutus Biopharma (Issuer)
Bishop Joseph E (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/06/2025
3:13 PM
Arbutus Biopharma (Issuer)
Hasija Anuj (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/03/2025
8:24 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/25/2025
6:05 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/25/2025
6:19 AM
Arbutus Biopharma (Subject)
Roivant Sciences Ltd. (Filed by)
Roivant Sciences Ltd. (Filed by)
Form SCHEDULE 13D/A
02/21/2025
8:00 AM
Arbutus Biopharma (Subject)
Whitefort Capital Management, LP (Filed by)
Form SCHEDULE 13D/A
02/19/2025
5:25 PM
Arbutus Biopharma (Issuer)
Sims Karen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
5:25 PM
Arbutus Biopharma (Issuer)
HASTINGS DAVID C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
5:25 PM
Arbutus Biopharma (Issuer)
McElhaugh Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
5:25 PM
Arbutus Biopharma (Issuer)
Naftzger J. Christopher (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2025
7:34 PM
Arbutus Biopharma (Subject)
Naftzger J. Christopher (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2025
7:36 PM
Arbutus Biopharma (Subject)
McElhaugh Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2025
7:38 PM
Arbutus Biopharma (Subject)
Sims Karen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2025
7:39 PM
Arbutus Biopharma (Subject)
HASTINGS DAVID C (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/03/2025
2:26 PM
Arbutus Biopharma (Subject)
MORGAN STANLEY (Filed by)
Form SCHEDULE 13G/A
01/13/2025
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/05/2024
11:15 PM
Arbutus Biopharma (Filer)
Form EFFECT
11/15/2024
10:03 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2024
7:41 AM
Arbutus Biopharma (Subject)
Two Seas Capital LP (Filed by)
Form SC 13G/A
11/06/2024
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/15/2024
7:26 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/11/2024
3:07 PM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/01/2024
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/10/2024
3:50 PM
Arbutus Biopharma (Subject)
MORGAN STANLEY (Filed by)
Form SC 13G
06/06/2024
10:16 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2024
5:00 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
The Man I Turn to In Times Like This (Ad)

A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.

Market chaos? Hear Tilson’s take now
05/28/2024
3:25 PM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/24/2024
3:07 PM
Arbutus Biopharma (Issuer)
Torti Frank (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2024
5:00 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/17/2024
8:03 AM
Arbutus Biopharma (Subject)
Whitefort Capital Management, LP (Filed by)
Form SC 13D/A
05/09/2024
7:00 AM
Arbutus Biopharma (Subject)
Whitefort Capital Management, LP (Filed by)
Form SC 13D
05/02/2024
3:32 PM
Arbutus Biopharma (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/02/2024
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/02/2024
6:26 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ABUS) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners